What are the implications of immune evasion in cancer therapy?
Immune evasion is a significant challenge in cancer therapy. Tumors can employ various strategies to escape immune detection, such as downregulating antigen presentation, secreting immunosuppressive cytokines, and expressing checkpoint proteins like PD-L1. These mechanisms hinder the effectiveness of traditional therapies and can lead to treatment resistance. Immunotherapies, including checkpoint inhibitors and adoptive cell transfer, are designed to overcome these obstacles by reactivating the immune system's ability to recognize and kill cancer cells.
